AstraZeneca and Mercado's PARP inhibitor Lipdro has been approved for listing by the National Drug Administration

today, AstraZeneca and Mersa East China jointly announced that its PARP inhibitor, Leopacho (Olapari, overseas, Lynparza), has been approved by the NationalMedicines(Supervisory Authority) for the first time in China to be approved for theof ovarian cancer."about Olapari
Olapari is an innovative first oral polypolydhocynucleic nucleocosin (PARP) inhibitor
drug(which can use defects in the tumor DNA damage response (DDR) pathway to kill cancer cells firstrelevant in vitro studies have shown that olapari-induced cytotoxicity may have been involved in the inhibition of PARP enzyme activity and contributed to the formation of the PARP-DNA complex, which ultimately led to DNA damage and cancer cell death, Olapari has beenby the U.SFDA (and approved by the European Union for the treatment of patients with advanced ovarian cancer with BRCA mutations), and was approved by the FDA earlier this year to treat patients with metastatic breast cancer who carry the BRCA gene mutation (gBRCAm) and human epidermal growth factor receptor 2 (HER2), which is negativestudiesin a clinicaltrialcalled Study19, where patients with platinum-sensitive recurrent plasma ovary cancer were found to receive a placebo with a spabo, extending PFS (no disease progression)subsequently, Phase III clinical study SOLO-2 also demonstrated that the Olapali group significantly extended PFS (median PFS19.1 months vs5.5 months) compared to the efficacy of placebo and standard chemotherapy in patients with BRCA mutation in ovarian cancer1 Follow-up data from late 19th of the year showed that, whether or not brca mutations were carried, Olapari as a maintenance therapy reduced the risk of disease progression or death by up to 65% and significantly improved the patient's progressionless survivalat the same time,, clinical trial results also show that in the single-drug treatment of advanced ovarian cancer, Olapari overall has good tolerance and safety, can be used for long-term support therapy, and Olapali treatment during the adverse reactions are light to moderate, reduced or discontinued can be alleviated